A GLOBAL COLLABORATION FOR EQUITABLE ACCESS TO BIOTECHNOLOGY
Manufacturing Diagnostics 101
Wed 17 March, 16:00-17:30 GMT
Virtual symposium featuring talks on diagnostic devices, from research and development to implementation. Join breakout sessions with researchers from Africa, Asia, Latin America and beyond to continue discussions on quality assurance, device design, and more. Participate to share your experiences and join Reclone Network working groups.
MANUFACTURING DIAGNOSTICS 101
|Virtual room opens
|Developing In-house RPA and its Applications in CRISPR Diagnostics, specifically SARS-CoV-2
|Dr Aimorn Homchan, Vidyasirimedhi Institute of Science and Technology, Thailand
|FarmaCoop’s history as a recovered pharmaceutical laboratory and their challenges in manufacturing SARS-CoV-2 diagnostic tests
|Bruno Di Mauro, as president of Farmacoop, and Biotechnologist Luciano Brum
|Breakout Rooms Open
|Room 1: Sharing Best Practices for RPA
|Room 2: What’s the best RT
|Room 3: Top Tips for Sharing Protocols
|Room 4: Show & Tell: Diagnostic Hardware
|Online room will be open for continued discussion
Dr. Aimorn Homchan, School of Biomolecular Science and Engineering, Vidyasirimedhi Institute of Science and Technology (VISTEC), Rayong, Thailand, Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok, Thailand
The collateral cleavage activity of CRISPR-associated nucleases, particularly Cas12 and Cas13, has been used as a basis for nucleic acid detection, including that of SARS-CoV-2. Common designs of CRISPR diagnostic methods combine an isothermal amplification step with a Cas-based detection step for maximal sensitivity and specificity. While CRISPR-based detection holds promise for use in low-resourced settings due to its accuracy, ease of use and minimal equipment requirement, the technology uses many biomolecular components, several of which are costly and proprietary. Here, I will describe our team’s efforts to locally produce and formulate recombinase-polymerase isothermal amplification (RPA), while concurrently improving several characteristics of RPA and CRISPR-based detection, particularly for the detection of SARS-CoV-2.
Bruno Di Mauro, President, and Luciano Brum, Biotechnologist, of Farmacoop
Farmacoop is a recovered company formed from Roux Ocefa Laboratory who went bankrupt after more than 80 years of work. The employees demanded to continue working and were able to create the cooperative. Through rebuilding the production and manufacturing plants, Farmacoop were able to receive certification to manufacture medical devices. Now, Farmacoop is developing a SARS-CoV-2 diagnostic test, named FarmaCov, using IgG antibodies to track positive cases as a complimentary assay to PCR that does not require highly skilled technicians.
Reclone Symposium 2.0: BENCH TO BEDSIDE: DEVELOPING AFFORDABLE DIAGNOSTICS
29 July 2020View talks from the previous symposium on YouTube!
|Link to Presentation
|Daniel Ndima, CapeBio
|Harnessing African indigenous biological resources to develop “Best-in-Class” biologics for diagnostics
|Dr Jacqueline Linnes, Purdue University, USA
|Designing user-friendly diagnostics